Talazoparib shows hint of considerable added benefit in breast cancer, says IQWiG

7 September 2020

Talazoparib is another drug from the substance class of PARP inhibitors, which also includes olaparib and rucaparib, for example, to have been approved this year for the treatment of breast cancer.

US pharma giant Pfizer (NYSE: PFE) won approval for Talzenna (talazoparib) in the European Union in June last year.

Besides, patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine-based therapy, unless this therapy is unsuitable for them.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK